Current Headlines

  1. Pfizer To Develop GHD Drug With OPKO Health
    12/18/2014

    Pfizer announced it has partnered with Miami-based OPKO Health to develop the latter's long-acting hGH-CTP as treatment for growth hormone deficiency (GHD) syndrome in both adults and children, as well as for growth failure in children born small for gestational age (SGA) who fall short of catch-up growth standard by 2 years old.

  2. EMA Backs MorphoSys' Orphan Application For MOR208 In DLCBL
    12/18/2014

    MorphoSys, a company specializing in developing therapeutic antibodies, announced that it has received the positive opinion of the European Medicines Agency for the Orphan Medicinal Product Designation application of its drug MOR208 as a treatment for diffuse large B-cell lymphoma (DLBCL).

  3. U.K., U.S. Collaboration Seeks To Repurpose Drugs As Neurological Treatments
    12/18/2014

    U.S. non-profit, Alzheimer’s Drug Discovery Foundation (ADDFF) and the Alzheimer’s Society U.K. (ASUK) announced they would be funding two separate clinical trials to establish alternate proof of concept and potentially repurpose two pipeline medications indicated for separate illnesses. One study will test the efficacy of an erectile dysfunction (ED) medication against vascular dementia, and the other will test a diabetes medication as an Alzheimer’s treatment.

  4. Carlina, Atlangram Partner On Osteoarticular Infectious Diseases Antibiotics
    12/17/2014

    Carlina Technologies has partnered with Atlangram to develop innovative antibiotics for osteoarticular infectious diseases.

  5. AMR Superbugs Could “Cast Medicine Back To The Dark Ages,” Says Study
    12/17/2014

    A new study commissioned by the British government estimates that by 2050, antimicrobial- resistant (AMR) disease could take 10 million lives per year and rack up a global cost of over $100 trillion. The figures reinforce the importance of investment in new, effective AMR drugs, Reuters reports.

  6. Potential Treatment For Drug-Resistant Skin Cancer Discovered
    12/17/2014

    The Wellcome Trust and Cancer Research UK have co-funded a study that has discovered potential skin cancer drugs which can multi-task and prove more potent than existing melanoma treatments.

  7. X-Chem, Alexion To Develop Drugs For Ultra-Rare Disorders
    12/17/2014

    X-Chem, a private biotech firm developing novel small molecule drugs via its DNA-encoded library platform, announced that it has entered into a drug discovery partnership with Alexion to jointly develop treatments for severe and ultra-rare disorders.

  8. Peregrine Reports Bavituximab Preclinical Results, Manufacturing In-House
    12/17/2014

    Peregrine Pharmaceuticals announced in a press release that its bavituximab antibody treatment met with success in preclinical trials. The company also announced in a conference call that it seeks to expand in-house manufacturing of the agent, rather than outsource it to a contract and development manufacturing organization (CDMO).

  9. Oncothyreon, Array BioPharma Restructure Agreement For ONT-380
    12/17/2014

    Oncothyreon and Array BioPharma have restructured their development agreement for ONT-380 (ARRY-380), an oral agent to treat metastatic breast cancer. The companies announced the deal in a press release,

  10. Researchers Develop Novel Antimicrobial Peptides To Combat ‘Superbugs’
    12/16/2014

    Researchers at the University of Pittsburgh’s Center for Vaccine Research (CVR) have developed a set of novel antimicrobial peptides that are more effective than traditional antibiotics at fighting different drug-resistant bacteria, including the notorious "superbugs".

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.